Diamond Hill Capital Invests in BioLife Solutions Due to High Switching Costs
In its Q2 2026 investor letter, Diamond Hill Capital Small Cap Strategy highlighted a new position in BioLife Solutions (NASDAQ:BLFS), citing the company's strong competitive advantage due to high switching costs. The biotechnology firm provides essential materials for cell and gene therapy manufacturing, supported by FDA Master Files and embedded into approved therapies and clinical trials. The fund outperformed the Russell 2000 Index in Q2 with a return of 24.01%, driven largely by strong stock selections in healthcare and industrials sectors. While AI-related stocks were market leaders due to their performance, Diamond Hill's underweight position in technology hurt relative returns. Looking ahead, the fund is focusing on resilient companies tied to infrastructure, defense modernization, and essential industries where long-term demand supports value creation.
Tickers: $BLFS
Topics: biotechnology health care portfolio management small-cap equities